Pharmaceutical & Biotech
News and Insights
Amgen – ‘Breakaway from Cancer’ Campaign
Patrick Dempsey, who played a doctor on "Grey's Anatomy" is starring in a new campaign for Amgen to help fight cancer. The campaign supports efforts for the prevention of cancer, support for those battling the disease, provides financial assistance and aids survivors. Dempsey's mother died from ovarian cancer in 2014. He founded the Patrick Dempsey Center for Cancer Hope & Healing in 2008. Click here to view the entire article ...
Changes coming to Novartis
In an effort to show the importance of oncology to Novartis, it will be splitting the company into two business units. One will be focused on cancer and the second on other drugs. Additionally, David Epstein, who has been with Novartis since 1989, will be departing the company later this year to pursue new opportunities in the US. He will be replaced by two people. Paul Hudson is coming over from AstraZeneca to lead the pharmaceutical business unit and Bruno Strigini, who currently head of Novartis Oncology, will take over as lead the newly created oncology business. Click here to view the entire article. ...
Express Scripts to implement a new program
In an effort to deter companies from increasing prices on older drugs, Express Scripts is starting a "market events" program that allow them to act quickly when a company unexplainably raises prices for older drugs. This is in response to Turing and Valeant 's increasing pricing for certain therapies this past year. The program will be optional to both employers and health insured clients. Customers that sign up will allow Express Scripts to move patients to lower-priced alternatives when an old drug's price increases. Click here to view the entire article. ...
Teva - Allergan deal scheduled to close in June
Teva is on track to finish its $40.5 billion dollar buy of Allergan's generics unit. The deal has been in the works since last summer and with recent ending of the Pfizer/Allergan buyout shareholders have been nervous. Click here to view the entire article. ...
Shire to build a biologics plant in Ireland
Shire is expected to begin construction on a $400 million biologics plant in Peircetown, Ireland this summer. The plant will employ 400 individuals and is expected to be completed in 2019. Currently, Shire only has manufacturing plants in the US. Shire CEO Flemming Ornskov said, "Increasing our biologics manufacturing capability is fundamental to achieving our ambition of becoming the world's leading Biotechnology Company focused on rare diseases and other specialty conditions." Click here to view the entire article. ...
Pfizer-Allergan merger collapses
In an effort to cut its tax rate, Pfizer's CEO, Ian Read, has been on a mission to move the company overseas. The $160 billion purchase of Allergan would have relocated Pfizer's headquarters to Ireland. Everything was running smoothly until the US Treasury Department put a new tax-inversion rule in place. After this, both companies decided to terminate the agreement. Pfizer will decide by the end of the year whether it will split into two separate businesses. Click here to view the entire article. ...
Positive results for Eli Lilly
Eli Lilly and research partner Incyte released good news from its Phase III study for a treatment for rheumatoid arthritis. The arthritis pill named baricitinib showed a 20% improvement in patient symptoms after a 12 week period when matched with placebo results. Click here to view the entire article. ...
J&J and AbbVie cleared for first-line treatment
When AbbVie bought J&J partner Pharmacyclics last year, it was counting on Imbruvica's potential to treat chronic lymphocytic leukemia (CLL). On March 4th, the FDA cleared the way for first-line treatment of patients with CCL. This approval comes from the results of a multi-center open label Phase III study. This is a big step for patients who are seeking an alternative to customary chemotherapy treatment. Click here to view the entire article. ...
FDA providing $2 million in new grants
The U.S. Food and Drug Administration has announced $2 million in funding for natural history studies in rare disease. The program titled, Orphan Products Natural History Grants Program, will help to shed a light on how specific rare diseases progress in individuals over time so that knowledge can inform and support product development and approval. Research grant applications are due by October 14, 2016. All responsive applications will be reviewed by a panel of rare disease and natural history experts. The anticipated start date of funding for grantees is March 2017. Click here to view the entire article. ...
The Essence of Executive Recruiters
This is an interesting article how important an the Executive Recruiter is to your job search. Honing in on the top 4 mistakes C-level executives make when searching for a job. Please take a moment to read a recently published articled in Forbes Magazine. Read more ...
1 of 3